Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 25 percent. This is a 7.69 percent increase over losses of $(0.13) per share from the same period last year.